Sanofi Wins Japan Approval for Wayrilz in Rare Blood Disease
PARIS, June 23, 2026 Sanofi has secured an important regulatory milestone after Japan’s Ministry of Health, Labour and Welfare...
Immune Thrombocytopenia
Advertisement
UCB and Biogen Report Positive Phase 3 Lupus Results for Dapirolizumab Pegol in The Lancet
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 1, 2026 UCB and Biogen announced the publication of full Phase 3 PHOENYCS...
Agios Expands Rare Hematology Portfolio with Global Cevidoplenib Licensing Deal
CAMBRIDGE, Mass., June 1, 2026 Agios Pharmaceuticals has entered an exclusive global licensing agreement with South Korea-based Oscotec to...
Sanofi Rilzabrutinib Wins Japan Orphan Status
Paris, March 2, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug...
Sanofi’s Wayrilz Approved in the U.S. as First BTK Inhibitor for Immune Thrombocytopenia
Sanofi has secured U.S. FDA approval for Wayrilz (rilzabrutinib), marking the first Bruton’s tyrosine kinase (BTK) inhibitor approved for...
Advertisement
